CURRICULUM VITAE
LEWIS B. Eberly, MD, PhD
Last updated March 2004

PLACE AND DATE OF BIRTH:
Lincoln, Nebraska, April 1, 1950

SEES PATIENTS AT:
Inova ALFA Neurology
1500 N. Beauregard St. #300
Alexandria, VA 22311
(703) 845-1500

Inova ALFA Neurology
8505 Arlington Boulevard #450
Fairfax, VA 22031
(703) 280-1234

CERTIFICATION:
Diplomate, American Board of Clinical Neurophysiology
Board Certified, American Board of Psychiatry & Neurology,
November 1994
American Board of Sleep Medicine, 2003

LICENSURE:
Commonwealth of Virginia
#0101-045384 (04-30-04)

EDUCATION:
The University of the South, 1968-1972
University Avenue
Sewanee, Tennessee 37375
B.A. Psychology, 1972

North Texas State University, 1972-1976
Avenue C & Chestnut Ave
Denton, TX 76203
Natural Science and Graduate Biology Courses

The University of Texas Medical Branch. 1976-1981
301 University Blvd.
Galveston. TX, 77550
Ph.D. in Neurophysiology, 1981

The University of Texas Southwestern Medical School
5323 Harry Hines Blvd.
Dallas, TX 75235
M.D.. 1981-1985

INTERNSHIP AND RESIDENCY:
Internship in Medicine, 1985-86
Texas Tech Medical Center
1400 Wallace Blvd.
Amarillo, TX 79106
Chairman, Roger Oskvig, M.D.

Neurology Residency
The University of Texas Southwestern Medical Center, 1986-89
Department of Neurology
5323 Harry Hines Blvd.
Dallas. TX 75235

Residency in Neurology
Chairman, Roger N. Rosenberg, M.D.
Parkland Memorial Hospital
5201 Harry Hines Blvd.
Dallas. TX 75235

Dallas Veterans Administration Medical Center
4500 South Lancaster Road
Dallas, TX 75206

FELLOWSHIP: Fellowship in Clinical Neurophysiology, 1989-90
The University of Texas Southwestern Medical Center
Chairman, Robert Leroy, M.D.

Training in Sleep Medicine and Clinical Polysomnography,
April 1990-August 1990
Sleep-Wake Disorder Center
Presbyterian Hospital of Dallas
8200 Walnut Hill Lane
Dallas, TX 75231
Chief. Philip Becker. M.D.

PROFESSIONAL SOCIETIES:
American Academy of Sleep Medicine
American Electrophysiology Society
American Epilepsy Society
American Medical Association
Medical Society of Northern Virginia

HOSPITAL APPOINTMENTS:
Inova Alexandria Hospital
4320 Seminary Road
Alexandria. VA 22304

Inova Fairfax Hospital
3300 Gallows Road
Falls Church, VA 22046

TEACHING ACTIVITIES:
Morning report and Neurology Rounds for house staff and
medical students of Georgetown University at Inova Fairfax Hospital

Teaching psychiatric residents at Inova Fairfax Hospital

PUBLICATIONS:

Original Papers:
Eberly. L. and Pinsker, H., "Neuroethological Studies of Reflex Plasticity in Intake Aplysia", Behavioral Neuroscience, 98:609-630, 1984.

Eberly, L., Dudley. C. and Moss, R., "Iontophoretic Mapping of Corticotrotropin Releasing Factor (CRF) Sensitive Neurons in Rat Forebrain. Peptides, 4:837- 1983.

Eberly. L., Kanz, J., Taylor, C. and Pinsker, H., "Environmental Modulation of a Central Pattern Generator in Freely Behaving Aplysia". Behavioral Neural Biology, 32: 21-32, 1982.

Kanz, J., Eberly, L., Cobbs, J. and Pinsker, H., "Neuronal Correlates of Siphon Withdrawal in Freely Behaving Aplysia", . Journal of Neurophysiology, 42: 1538-1556, 1979.

Pinsker. H., Eberly, L., -Whole Nerve Cuff Electrodes in Neurothological Studies"- -Journal of Electrophysiological Techniques, 1982.

Pinsker, H., Eberly, L., "Spike T ' Analysis ' Neuroethological Studies", Journal of Electrophysiological Techniques, 1982.

ABSTRACTS:

Eberly, L., Pinsker, H., "Role of Interneuron II in Long-Term Sensitization of Siphon Withdrawal in Aplysia Califonica". Neuroscience Abstract, 4:192, 1978.

Eberly, L., Pinsker, H., "Spike Train Analysis of Identified Siphon Motorneurons in Intake Aplysia and Subsequently Reduced Preparations", Neuroscience Abstract, 6:13.2. 1980.

Eberly, L. Lasseter, M., Pinsker, H., "Phase Response Curves and Entrainment of the Interneuron 11 Oscillator in Intact Behaving Aplysia", Neuroscience Abstract, 5:244, 1979.

Pinsker. H., Lasseter, M. and Eberly, L., Analysis of Population Activity in Whole--Nerve Recordings from Aplysia", Fed Procedures Abstract, 3 8:3 - 13 94, 1979.

RESEARCH:

Sub-investigator: Baker Norton Protocol IX- 1 O'l-002: Cervene: Modification of outcome in patients with acute ischemic stroke. A double blind, randomized, placebo-controlled, parallel group- dose comparison stud by 24 hour infusion, July. 1995.

Hoechst Marion Roussel Protocol VGPR-0101: Efficacy of rational polytherapy with Sabril (Vigabatrin) monotherapy in the management of patients with non-refractory complex partial seizures, September, 1995.

Wyeth-Ayerst Protocol 897-Al-307-US and 897-Al-212-US: A double-blind safety, tolerance and efficacy study of Zaleplon in adult outpatients with insomnia, September, 1995.

Sub Investigator: Boehringer lngelheim A Phase 2'/3 multi-center, double-blind, placebo controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of two doses of IV Aptiganel HCL versus placebo in patients with acute ischemic stroke, 1996. Sub Investigator Lorex Pharmaceuticals: LES02: Assessment of the efficacy and safety of efficacy patients with acute ischemic stroke, 1996.

Sub Investigator: Knoll Pharmaceuticals Ancrod: Parallel, Group Sequential, Double-Blind, Randomized. Placebo- Controlled Study of the Safety and Efficacy of IV Ancrod given within 3 hours after the onset of Acute Ischemic Stroke, June, 1996.

Sub Investigator: Boehringer Ingelheim Inc: a Phase 2/'3 multi-center, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of two IV Aptiganel Hydrochloride versus placebo in patients with acute ischemic stroke, 1996.

Sub Investigator: Pfizer/Eisai: An open-label, multi-center clinical trial evaluating the safety and efficacy, of Donepezil HCL (E2020) in patients with Alzheimer's Disease. 1996.

Sub Investigator: Zeneca: A multi-center, double-blind, randomized comparison of Zolmitriptan and Sumatriptan in the acute treatment of multiple migraine headaches, 1997.

Sub Investigator: Novartis: An open-label study to evaluate the safety and efficacy of 1.5 nig BB) through 6 mg BID of Exelon in patients with mild to severe probable Alzheimer's Disease in the community setting, 1997.

Sub Investigator: Eisai: A 24 week, Multi-center, double-blind, placebo-controlled evaluation of die efficacy and safety of Donepezil Hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease, 1997.

Sub Investigator: Pozen: A single dose, double blind, dose ranging, placebo-controlled safety and efficacy, study, of various doses of Naproxen Sodium mid Metoclopramide in subjects with acute migraine headaches, 1997-

Sub Investigator: GlaxoWellcome: S2WA4003. A randomized double blind, double dummy, active placebo controlled, parallel group evaluation of oral Naratriptan (2.5mg) compared to Oral Naproxen Sodium (275iiig) on Migraine related quality of life, 1997.

Co-Investigator: Algos: Morphine with Dextromethorphan versus Morphine in cancer and other chronic pain, 1997.

Sub Investigator: Icos Phase 2 Study of Hu23F2G in Acute Exacerbation of Multiple Sclerosis, 1997-98.

Sub Investigator: Glaxo Wellcome. Open Randomized comparison of Add-on Lamotrigine or Valproate/Carbomazepine withdrawing to Monotherapy in Patients With Treatment Resistant Epilepsy. 1998.

Sub- Investigator: Abbott: The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis-. A Double-Blind, Placebo-Controlled Study, 1998

Sub-Investigator: Janssen: Placebo Controlled evaluation of galantamine in the treatment of Alzheimer's Disease: Safety and efficacy under a slow-titration regime, 1998.

Principal-Investigator: Parke-Davis: Pregabalin BID Add-On Trial: A Randomized, Double-Blind, Placebo Controlled, Parellel Group, Multicenter Study iii. Patients with Partial Seizures, 1998

Sub-Investigator: Bristol-Myers Squibb: A Double-Blind, Placebo Controlled, Safety, Efficacy and Dose response trial of two intravenous doses of BMS-204352 in Patients with acute stroke, 1998.

Sub-Investigator: Targon: A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group Study of Morphelan in patients with chronic, moderate to severe pain, 1999.

Sub- Investigator: Centaur: A 90 day Safety Study of CPI-1189 in male and female Parkinson's patients on L-Dopa plus Carbidopa, 1999.

Sub-investigator: Janssen: Placebo controlled evaluation of galantamine in the treatment of Alzheimer's Disease, 1999.

Principal Investigator: Parke-Davis: Pregabalin add-on trial: A randomized, double-blind. placebo controlled study in patients with partial seizures 1999.

Sub-investigator: Pfizer: A Multi-center trial to evaluate the efficacy, tolerability and subject satisfaction with Eletriptan in the treatment of migrane headache attacks in Neurology practices, 1999.

Principal investigator: R.W. Johnson: A randomized, double-blind, parallel group. monotherapy study to compare the safety and efficacy, of two doses of Topiramate in the treatment of newly diagnosed or recurrent epilepsy. 1999.

Sub Investigator: R.W. Johnson: A double-blind in, placebo-controlled, parallel group, dose response study, to evaluate the efficacy and safety of Topiramate versus placebo in the relief of pain in diabetic peripheral neuropathy, 1999.

Principal Investigator: GlaxoWellcome: An Open-Label Evaluation of the Long-Term Safety or Oral Naratriptan 1mg Twice Daily as Short-Term Prophylactic Treatment for Menstrually-Associated Migraine. 2000.

Sub- Investigator: Glaxo Wellcome: A Randomized, double Blind, Placebo Controlled, parallel group, single attack evaluation of Sumatriptan 5C,nig and 100mg versus placebo during a migraine headache at the first sign of pain, 2000.

Sub- Investigator: R.W. Johnson: A randomized, double-blind, placebo-controlled parallel group, dose response study to evaluate the efficacy and safety of Topiramate in the prophylaxis of migraine. Feb. 2001.

Sub- investigator-. Praecis Pharmaceuticals: A randomized, double-blind. , parallel Group Study, of the safety, and efficacy of Latranal compared to Doxepin Cream and Placebo in patients with chronic low back pain, Feb. 200 1.

Sub- investigator: Novartis: Trileptal Diabey6c Neuropathy Phase IV study, March 2001

Sub Investigator: Janssen Research GAL-INT-26 Cerebral Vascular Dementia, August 2001

Sub Investigator: AstraZeneca Zanadu Zomig ZMT: Open Label Comparison of the Effects of Zomig and ZMT and Usual Migraine Care on Work Loss. Productivity, and Patient Preference December 2001.

copyright and legal notices
Site developed by Continuum Marketing Group LLC

Alexandria Office: 1500 North Beauregard Street, Suite 300, Alexandria, Virginia 22311
phone: (703) 845-1500   fax: (703) 845-1300

Fairfax Office: 8505 Arlington Boulevard, Suite 450, Fairfax, Virginia 22031
phone: (703) 280-1234   fax: (703) 280-1235

www.alfaneuro.com